Hosted by Trinity College Dublin, the 2016 International Cancer Conference is the 10th on the theme “New Frontiers in Personalised Cancer Care”. An outstanding group of international speakers will give talks on advances in Cancer Prevention, Immunotherapy, Surgical Oncology, Radiotherapy and Targeted Therapeutics.
The conference features a keynote Burkitt Lecture to be delivered by the 2016 Burkitt Medal Awardee, who will be honoured at the conference dinner held in Trinity’s magnificent Dining Hall.
The International Cancer Conference was established through a tripartite agreement developed in 1999 by the Departments of Health in Ireland and Northern Ireland and the US Administration. Trinity in association with St James’s Hospital Dublin continues to host this conference.
Health professionals, cancer clinicians and clinical scientists, scientists working in cancer, representatives of pharmaceutical companies involved in oncology, policy makers, post-doctoral researchers within medicine and science will benefit from participation in the conference.
The conference has been approved by the Royal College of Physicians of Ireland for 12 CPD credits. 1 CPD credit is equivalent to 1 hour of educational activity.
There is one major international airport in Dublin, situated approximately 10km north of the city centre. Dublin is easily accessible from the UK, Continental Europe and the east and west coast of the USA.
Access from Dublin Airport to Dublin City
There are a number of private and public bus services that operate from outside the airport arrivals terminal: Aircoach, a privately run bus service, operates between the airport and a number of city hotels and locations. www.aircoach.ie
Airlink (bus 747), operated by Dublin Bus, will bring you directly from the airport to Busaras, the central bus station, located in the city. www.dublinbus.ie
There are also a number of other public bus services operating between the airport and various destinations
It is also possible to get to Dublin by ferry via Hollyhead, Liverpool and Isle of Man ports in Britain. Dublin has two ferry terminals – Dublin Port, located in the city centre, is serviced by bus and Dun Laoghaire ferry terminal, south of the city, is easily reached by a 20 minute car or DART train journey.
Trinity College Dublin has preferential agreements (applicable to weekdays only, if available) with the following hotels close to the conference venue:
|Trinity City Hotel|
|Phone:||353 (0) 1 6481000|
|Fax:||353 (0) 1 6481010|
|Clayton Hotel Cardiff Lane|
|Phone:||353 (0) 1 6439500|
|Fax:||353 (0) 1 6439510|
|Address:||Sir John Rogerson's Quay,
|O'Callaghan Hotels Dublin|
|Contact:||Maria Lawlor/Jeremy O’Keeffe|
|Phone:||353 (0) 1 6073900|
|Fax:||353 (0) 1 6615663|
O'Callaghan Hotels has three
Mont Clare Hotel
Conference dinner is not included in the conference registration fee and needs to be booked separately.
The dress code for the dinner is business attire.
|9.00 – 9.20||WELCOME ADDRESS AND CONFERENCE OPENING|
|SESSION 1:||ADVANCES IN CANCER PREVENTION|
|Chair: Professor Cara Martin, Assistant Professor in Molecular Pathology and Tumour Biology, Department of Pathology, The Coombe Women and Infants University Hospital & Trinity College Dublin|
|9.20||Advances in Cancer Prevention|
|Professor Elisabete Weiderpass, Professor of Medical and Cancer Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden|
|9.50||New Opportunities for Personalised Cancer Prevention|
|Professor Catherine Hayes, Associate Professor Public Health Medicine, Trinity College Dublin, Ireland|
|10.20||Short Talk: HPV Primary Screening Pilot Study|
|Dr Christine White, Department of Histopathology, Trinity College Dublin, Dublin, Ireland and the Coombe Women and Infants University Hospital, Dublin, Ireland|
|10.35||Short Talk: Frequency of BRCA 1 and BRCA2 mutations in an unaffected Irish cohort|
|Michael Farrell, CNS in Cancer Genetics, Clinical Cancer Genetics Department, Mater Private Hospital, Dublin|
|10.50 - 11.30||Coffee Break and Poster Viewing|
|SESSION 2:||ADVANCES IN CANCER IMMUNOTHERAPY|
|Chair: Professor Derek Doherty, Associate Professor and Head of Immunology, Trinity Translational Medicine Institute and St. James’s Hospital|
|11.30||Enhancing the Efficacy of Cancer Immunotherapeutics and Vaccines Using Inhibitors of Immune Checkpoint and Treg Cells|
|Professor Kingston Mills, Professor of Experimental Immunology, Head Immunology, Inflammation and Infection Research Theme, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland|
|12.00||In Vivo Discovery of Novel Targets for Cancer Immunotherapy|
|Professor Kai Wucherpfennig, Chair of the Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Professor, Neurology, Harvard Medical School, Boston, USA|
|12.30||Adoptive T cell Therapy for Cancer|
|Dr David Gilham, Reader, Clinical and Experimental Immunotherapy Group, Institute of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, UK|
|13.00||Short Talk: Immunotherapy options for the obese cancer patient|
|Dr Joanne Lysaght, Department of Surgery, Trinity Translational Medicine Institute, St. James’s Hospital|
|13.15||Short Talk: HLA-DR is an independent prognostic indicator of patient survival in oesophageal adenocarcinoma|
|Dr Margaret Dunne, Department of Surgery, Trinity Translational Medicine Institute, St. James’s Hospital|
|13.30 - 14.20||Lunch and Poster Viewing|
|SESSION 3:||ADVANCES IN SURGICAL ONCOLOGY|
|Chair: Professor John Reynolds, Head of Surgery and Consultant Surgeon, Trinity Translational Medicine Institute and St. James’s Hospital|
|14.20||Robotic Thoracolaparoscpic Oesophagectomy for Esophageal Cancer|
|Professor Richard van Hillegersberg, Gastrointestinal Oncologic Surgeon, University Medical Center Utrecht, The Netherlands|
|14.50||Quantitative Imaging as a Potential Biomarker of Outcome|
|Professor William R. Jarnagin, Chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair in Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA|
|15.20||Molecular Staging of Oesophageal Cancer - Moving Beyond Shades of Purple|
|Mr Christopher Peters, Clinical Senior Lecturer and Consultant Upper GI and General Surgeon, Imperial College London, UK|
|15.50 - 16.20||Coffee Break and Poster Viewing|
|16.20||Introduction of the 2016 Burkitt Medal Awardee|
|Professor Owen Smith, CBE, Professor of Paediatric and Adolescent Medicine at University College Dublin and Consultant Paediatric Haematologist at Our Lady’s Children’s Hospital, Crumlin, Dublin, Honorary Regius Professor of Physic (1637) in the School of Medicine, Trinity College Dublin|
Cancer Prevention: from Denis Burkitt to the Human Genome Project
|19.00||Conference Dinner in Trinity College Dining Hall and Presentation of the 2016 Burkitt Medal (for delegates registered for the dinner in advance)|
|SESSION 4:||ADVANCES IN RADIOTHERAPY|
|Chair: Professor Jacintha O’Sullivan, Associate Professor, Department of Surgery, Trinity Translational Medicine Institute, St. James’s Hospital|
|9.00||Personalised in Situ Tumour Vaccination by Radiation and Immunotherapy|
|Professor Sandra Demaria, Professor of Radiation Oncology and Pathology, Weill Cornell Medical College, New York, USA|
|9.30||Novel Concepts of Clinical Research in Radiation Oncology|
|Professor Philippe Lambin, Head of Department, Maastricht Radiation Oncology Lab, University of Maastricht, The Netherlands|
|10.00||Short Talk: A novel role for the complement cascade in chemoradiation therapy resistant oesophageal adenocarcinoma|
|Dr Niamh Lynam Lennon, Department of Surgery, Trinity Translational Medicine Institute, St. James’s Hospital|
|10.15 - 10.45||Coffee Break and Poster Viewing|
|SESSION 5:||ADVANCES IN TARGETED THERAPEUTICS/PRECISION MEDICINE|
|Chair: Professor Lorraine O’Driscoll, Associate Professor of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin|
|10.45||Role of the Inflammasomes in Intestinal Inflammation|
|Professor Gabriel Núñez, Paul de Kruif Professor, Department of Pathology, University of Michigan, Ann Arbor, USA|
|11.15||Precision Medicine in the Breast Cancer Arena: Insights from National and International Collaborative Networks|
|Professor William Gallagher, Professor Cancer Biology, Director, Conway Institute, University College Dublin, Dublin, Ireland|
|11.45||Mapping the PTM Landscape in Health and Disease|
|Dr Yifat Merbl, Department of Immunology, The Leonard and Carol Berall Career Development Chair, Weizmann Institute of Science, Israel|
|12.15||Short Talk: A novel digital pathological approach to definitively identify CTCS|
|Dr Cathy Spillane, Department of Histopathology, Trinity College Dublin, Dublin, Pathology Research, The Coombe Women & Infants University Hospital, Dublin,
The Biomedical Diagnostics Institute, Dublin City University, Dublin, Ireland
|12.30||Short Talk:Extracellular Vesicle studies identify the potential diagnostic relevance of miR-134 as a biomarker for Triple Negative Breast Cancer and as a potential therapeutic option|
|Ms Michelle Lowry, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin|
|12.45||Short Talk:Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies|
|Dr Dania Movia, Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, and AMBER Centre, CRANN Institute, Trinity College Dublin, Dublin, Ireland|
|13.00 - 14.00||Lunch and Poster Viewing|
|SESSION 6:||ACADEMIC CANCER CENTRES|
|Chair: Professor Paul Browne, Head of School of Medicine and Consultant Haematologist, Trinity Translational Medicine Institute and St. James’s Hospital|
|14.00||The Role of Accredited Comprehensive Cancer Centres in the Drive for Personalised Cancer Care|
|Mr Simon Oberst, Accreditation and Designation WG Chairperson of the OECI|
|Professor John O’Leary, Chair of Pathology, Cancer Theme Leader, Trinity College Dublin|
|15.10||Awards for Best Proffered Papers and Posters|
|Close of Conference|
Professor of Radiation Oncology and Pathology, Weill Cornell Medical College, New York, USA
Sandra Demaria, MD, a native of Turin, Italy, obtained her MD from the University of Turin, and then moved to New York City for her post-doctoral training in immunology, followed by a residency in anatomic pathology at New York University School of Medicine, where she remained on the faculty until August 2015 raising to the rank of professor. She is currently Professor of Radiation Oncology and Pathology at Weill Cornell Medicine Medical College. Dr Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. Her laboratory was the first to show that radiotherapy can convert tumours unresponsive to immune checkpoint inhibitors into responsive ones, a finding being translated in several clinical trials at multiple institutions. Her current work is funded by the US National Cancer Institute and several private foundations and is aimed at identifying the molecular mechanisms that regulate ionising radiation’s ability to generate an in situ tumour vaccine in both preclinical tumour models as well as cancer patients treated in clinical trials testing various combinations of radiation and immunotherapy. As a breast cancer pathologist Dr Demaria has also studied the immunological microenvironment of breast cancer in patients. She holds leadership positions in national professional societies, including the Radiation Research Society, the Society for Immunotherapy of Cancer (SITC) where she currently serves on the Board, and is a member of the Steering Committee of AACR Cancer Immunology Working Group. She serves in the editorial board of several journals, including Radiation Research, The Journal of Immunology, Clinical Cancer Research and Journal for ImmunoTherapy of Cancer.
Professor of Cancer Biology, Director, Conway Institute, University College Dublin, Ireland
Professor William Gallagher is the Director of the UCD Conway Institute and a Professor of Cancer Biology in the UCD School of Biomolecular & Biomedical Science. He is also currently Director of BREAST-PREDICT, which is the first Irish Cancer Society Collaborative Cancer Research Centre (CCRC) to be funded. This country-wide CCRC, which is supported to the level of 7.5 million euro, runs from 2013 to 2018 and involves 6 academic institutions (University College Dublin, Trinity College Dublin, Royal College of Surgeons in Ireland, Dublin City University, NUIG and University College Ccork), as well as the not-for-profit clinical trials organisation, the All-Ireland Co-Operative Oncology Research Group (ICORG). Professor Gallagher was also co-PI and Deputy Co-ordinator of a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer (2009-2015) (; this was one of the most extensive organ-independent research programmes in the translational cancer research arena within the Republic of Ireland and involved comprehensive interactions with a range of major pharmaceutical, biotechnology and imaging companies.
Professor Gallagher currently co-ordinates the FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) programme, SYS-MEL , which is focused on applying systems medicine approaches to development of new diagnostic solutions in melanoma [this programme involves 6 partners (4 academic/2 industrial) across 3 EU countries and runs from 2013-2017]. He is also co-ordinator of a large-scale FP7 collaborative project, entitled RATHER, which is focused on providing new rationalised therapy options for difficult-to-treat breast cancer subtypes (2011-2016). This multi-million euro project involves 6 academic groups and 2 industrial parties across 5 EU countries.
A major focus of Professor Gallagher’s research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team (the Cancer Biology and Therapeutics Lab) investigates the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents.
Professor Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St Luke's Silver Medal Award in 2008, and the RAMI Doctors award in Oncology in 2013. Professor Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research, and has filed multiple patents. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids (www.oncomark.com). Professor Gallagher is currently the Chief Scientific Officer (CSO) at OncoMark.
Associate Professor Public Health Medicine, Trinity College Dublin, Ireland
Catherine Hayes obtained her undergraduate medical degree from University College Cork. Having completed a Training Scheme for General Practice, she then completed Higher Specialist Training in Public Health Medicine. She holds a Master in Public Health and Medical Doctorate from University College Dublin. Subsequent to this she was appointed Consultant in Public Health Medicine in the Health Service Executive (HSE) and continues to retain a commitment to the Health and Wellbeing Directorate of the HSE. She was appointed Associate Professor of Public Health at Trinity College Dublin in the Discipline of Public Health and Primary Care in 2011.
Her research interests lie in in the development, implementation and evaluation of interventions on lifestyle factors associated with cancer prevention, development and progression. She is a member of the All-Ireland NCI Cancer Consortium. She attended NCI for Public Health aspects of Cancer Prevention Curriculum in 2013 and Molecular aspects of Cancer Prevention in 2015. She is a former Board member of the Faculty of Public Health Medicine of the Royal College of Physicians in Ireland and is co-chair of the Royal College of Physicians Policy Action Group on Obesity. She currently serves on the UK and Ireland Society for Social Medicine Committee
Clinical Senior Lecturer and Consultant Upper GI and General Surgeon, Imperial College London, UK
Christopher Peters went to medical school in Leeds and stayed there to complete his junior surgical training. After a brief fellow job in London he moved to Cambridge to carry out a PhD with Professor Rebecca Fitzgerald. During his PhD he developed a four gene signature to predict outcome in oesophageal adenocarcinoma which was validated in 371 independent cases. With Rebecca he also set up the OCCAMS collaboration which went on to be selected to run the International Cancer Genome Consortium's Whole Genome sequencing project in oesophageal adenocarcinoma. OCCAMS has ongoing CRUK funding and is now recruiting in excess of 500 patients per year from 11 centres.
After returning to London to complete his higher surgical training he was appointed as a Clinical Senior Lecturer and Consultant Upper GI surgeon at Imperial College London with a specialist interest in oesophageal and gastric cancer. His academic interest is molecular and clinical predictors of outcome in Oesophageal adenocarcinoma, in particular developing ways of combining the two to improve stratification of patients, thereby improving management strategies.
Chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair in Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
Dr William R. Jarnagin was raised in outside of Boston, Massachusetts, and earned his undergraduate degree from Dartmouth College in 1982, a Master’s degree from Brandeis University in 1984 and an MD from Rush Medical College in 1988. He completed his training in general surgery at the University of California, San Francisco, in 1996. From 1990 to 1993, he completed a research fellowship at the Liver Center Laboratory at San Francisco General Hospital. In 1996-97, he served as the Hepatobiliary Fellow at Memorial Sloan-Kettering Cancer Center (MSKCC). Since 1997, he has been an attending surgeon at Memorial Sloan-Kettering Cancer Center, where he has served as Chief of the Hepatopancreatobiliary Service since 2008 and was a Vice-Chairman of the Department of Surgery from 2006 to 2010. He holds the Benno C. Schmidt Chair in Surgical Oncology at MSKCC and is Professor of Surgery at Weill Medical College of Cornell University.
Dr Jarnagin’s research has focused on genomics, novel therapies and biomarkers of treatment response in patients with biliary cancer, intraoperative navigation during hepatic resection and intraoperative blood conservation strategies during liver and pancreas resection. He has authored or co-authored 350 articles in peer-reviewed journals, over 60 chapters or invited reviews and has edited or co-edited three textbooks. He is the HPB Section Editor for Annals of Surgical Oncology and is a member of the editorial board of the Journal of the American College of Surgeons, and HPB. He is a member of several surgical societies, including SUS and ASA, and has been a member of the AHPBA Executive Council since 2004, serving as the Program Chair in 2007-08, Treasurer in 2009-11 and President in 2012-2013. He currently serves on the IHPBA Executive Council as the association’s Treasurer.
Head of Department, Maastricht Radiation Oncology Lab, University of Maastricht, The Netherlands
Professor Philippe Lambin is a clinician, radiation oncologist, pioneer in translational research with a focus on hypoxia, imaging and Decision Support Systems. He has a PhD in radiation biology and is Professor at the University of Maastricht (Radiation Oncology). He is co-author of more than 385 peer reviewed scientific papers and co-inventor of more than 15 patents. His main areas of interest are directed towards translational research in radiation biology with a specific focus on tumour hypoxia, functional imaging (CT-PET), lung and head and neck cancer. He has a recent interest in the development of multifactorial ‘treatment decision support system’ (www.predictcancer.org). He has been a visiting professor at the University of Leuven, Philadelphia and Toronto.
Department of Immunology, The Leonard and Carol Berall Career Development Chair, Weizmann Institute of Science, Israel
Dr Yifat Merbl completed her BS summa cum laude in Computational Biology at Bar Ilan University in 2003. She earned an MSc in immunology at the Weizmann Institute in 2005 with Professor Irun Cohen and joined the first PhD programme in systems biology at Harvard Medical School, completing her PhD there in 2010. She stayed on at Harvard as a postdoctoral fellow until joining the Department of Immunology at the Weizmann Institute in 2014.
Dr Merbl’s research explores the many modifications that proteins undergo in the human body. Drawing on her background in computational biology, cell biology, biochemistry, and immunology, Dr Merbl developed a high-throughput system that enabled her to monitor post-translational modifications of thousands of proteins in parallel, under conditions that are relatively close to those of the complex cellular environment. In addition, she developed a profiling system using protein microarrays that allow her to identify the changes that occur to thousands of individual proteins, simultaneously. In her new lab, Dr Merbl wants to zero in how the ubiquitin system, one of the most important post-translation modifiers in the process of cell division, controls the macrophages that have been shown to play a role in various human disorders ranging from inflammatory diseases (e.g. rheumatoid arthritis, inflammatory bowel disease) to cancer.
Her scholarships and awards include a pre‐doctoral fellowship in the Department of System Biology at Harvard Medical School, the Horowitz Center for Complexity Science Award in 2005, the Sarah Werch Research Scholarship in 2004, and the Sara Rottenberg Scholarship in Cancer Research at the Weizmann Institute in 2003. She received the 2000 President’s Excellence Award at Bar‐Ilan University. In 2014, she was also selected to join the Israeli Centers of Research Excellence (I-CORE) programme in structural biology of the cell. Dr Merbl received the ERC (European Research Council) starting grant award in 2015. She is the author of five patents, including one for the application of her protein profiling system to clinical diagnostics and biomarker discovery.
Professor of Experimental Immunology, Head Immunology, Inflammation and Infection Research Theme, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
Kingston Mills is Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity College Dublin (TCD). He is Head of The Centre for the Study of Immunology at Trinity Biomedical Sciences Institute and Theme Champion for Immunology, Inflammation and Infection at TCD. He is a graduate of TCD and trained at as a Postdoctoral Fellow at University College London and the National Institute for Medical Research, Mill Hill, London, before joining the Scientific Staff of National Institute for Biological Standards and Control (NIBSC), UK. He returned to Ireland in 1993 to take up an academic position at National University of Ireland, Maynooth. He was appointed to a Personal Chair at Trinity College Dublin in 2001 and was Head of the School of Biochemistry and Immunology from 2008 to 2011. He heads an active research team focusing on T cells in infection, autoimmunity and cancer. He is co-founder of Opsona Therapeutics and TriMod Therapeutics, biotech companies focusing on the development of immunotherapeutics for inflammatory diseases and cancer.
Paul de Kruif Professor, Department of Pathology, University of Michigan, Ann Arbor, USA
Gabriel Nuñez earned his MD degree from the University of Seville, Spain, in 1977. He received postdoctoral training in immunology at the University of Texas Southwestern Medical Center, Dallas (1979-1984) and residency training in Anatomical Pathology at Washington University in St Louis (1985-1990). In 1987, he joined the laboratory of Stanley Korsmeyer at Washington University, where he studied the function of the anti-apoptotic protein BCL-2. In 1991, he joined the Department of Pathology at the University of Michigan in Ann Arbor as an Assistant Professor and was promoted to full Professor in 2001. He holds the Paul de Kruif Endowed Professorship in Academic Pathology. His laboratory identified NOD1 and NOD2, the first members of the Nod-like receptor (NLR) family, a class of pattern-recognition receptors that mediate cytosolic sensing of microbial organisms. Nuñez and colleagues showed that genetic variation in a NLR family member, NOD2, is strongly associated with susceptibility to Crohn's disease. Dr Nuñez is the author of more than 300 scientific publications that have resulted in more than 70,000 citations (h-index 132, Google Scholar). His research programme is supported by grants from the National Institutes of Health.
Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute, Professor, Neurology, Harvard Medical School, Boston, USA
Dr Wucherpfennig received his MD in 1986 and his PhD in 1987 from the University of Goettingen, Germany. He completed research fellowships at Brigham and Women's Hospital and the Department of Molecular and Cellular Biology, Harvard University. In 1995, he joined the Dana-Farber Cancer Institute (DFCI), where he is principally involved in basic laboratory research that focuses on T cell immunology and the role of T cells in cancer immunology.
Gastrointestinal Oncologic Surgeon, University Medical Center Utrecht, The Netherlands
Richard van Hillegersberg attended medical school in Rotterdam, the Netherlands. In 1990 he received a research grant from the Dutch Digestive Foundation that enabled him to perform PhD research on the local treatment of liver metastases at the Department of Surgery, Erasmus MC in Rotterdam. In 1993 he received his PhD with honor. After obtaining his MD in 1994, he was a resident of Surgery in Rotterdam and was registered as general surgeon in 2000. From 2001-2002 he was a fellow of Surgical Oncology in the Academic Medical Center and Antoni van Leeuwenhoek Netherlands Cancer Center Amsterdam. Since 2003 he is appointed as staff surgeon at the University Medical Center Utrecht. From 2009 he is a full professor of gastrointestinal oncology and program leader of the GI-Oncology department. His clinical interests focuses on upper gastrointestinal tract surgery. Research is focused on minimally invasive and robotic surgery, surgical imaging, genetic profiling and radiofrequency ablation for cancer. He has authored and co-authored over 250 articles in international peer-reviewed journals. He is past president of the Dutch GI Surgical Association, board member of the Dutch Surgical Association and board member of the Dutch Society for liver surgery and is currently President of the Dutch Upper GI Surgery and President of European Digestive Surgery.
Head of the Genetics Section of the International Agency for Research on Cancer (IARC/WHO), Lyon, France
The research focus of Dr. Brennan’s group has two primary aims (i) identifying cancer predisposition genes through either genotyping or sequencing of very large numbers of cases and controls, and (ii) using biomarkers to help identify non-genetic risk factors for cancer, and even help identify early stage cancers. His group works with colleagues in many different parts of the world, with active field work studies underway in central and eastern Europe, central and south-east Asia, and Latin America.
Reader, Clinical and Experimental Immunotherapy Group, Institute of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester
Dr. Gilham obtained his PhD from the University of Dundee in 1996 before moving to Bristol University to work with Professor Robert Hawkins on T cell immunotherapy. The group moved to the Paterson Institute for Cancer Research in Manchester in 1998 where the focus upon T cell immunotherapy and Chimeric Antigen Receptor (CAR) T cells continued. In 2008, Dr. Gilham was appointed Senior Research Fellow to lead the laboratory research group. In 2015, the group moved into the Manchester Cancer Research Centre and Dr. Gilham appointed to Reader in 2016. Dr. Gilham is also a co-founder of Cellular Therapeutics, a University spin-out company focused upon producing clinical grade cell products.
The Clinical and Experimental Immunotherapy group is currently focused upon three main areas of study. The first involves understanding the phenotype and function of T cells within the tumour environment. The second focuses upon engineering T cells including investigating the biology of CARs and to improve the approach through T cell engineering and, finally, translating these approaches into clinical trials.
Professor of Medical and Cancer Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
Elisabete Weiderpass, MD, MSc, PhD, is a Professor of Medical and Cancer Epidemiology at the Karolinska Institutet in Stockholm, and a senior researcher and head of the Department of Research at the Institute of Population Based Cancer Research and Cancer Registry of Norway in Oslo. She is also actively involved in research and training at University of Tromsø and Samfundet Folkhälsan in Helsinki.
Elisabete serves as an expert in several scientific committees and advisory boards of organisations, such as the International Agency for Research on Cancer, World Health Organization, World Bank, Bill and Melinda Gates Foundation, World Cancer Research Fund, Norwegian Research Council, Norwegian Programme for Global Health and Vaccination (GLOBVAC), Danish Cancer Society, French National Cancer Institute (INCA), French INSERM, French Agence Nationale de Sécurité Sanitaire (ANSES), French Institute National Recherche Securite (INRS), French Foundation for Cancer Research (ARC), and Center of Diseases Control (CDC) in Gansu Province, China.
Elisabete has been frequently invited as a speaker at international cancer conferences and acts as a cervical cancer prevention activist.
Accreditation and Designation WG Chairperson of the OECI
Simon Oberst is a Fellow of the Institute of Chartered Accountants of England and Wales. After graduating in History from Trinity College Cambridge he began his career in the City of London and the North-East of England with KPMG and PwC. He specialised in the taxation of international companies and high net worth individuals. After moving into the charity sector, he spent six years with Macmillan Cancer Support as Director of Improving Cancer Services, a strategic role interacting with the NHS and the Department of Health. His current role is Director of Clinical Development of the Cambridge Cancer Centre, working with colleagues within Cambridge University Hospitals and the CRUK Cambridge Institute on the Strategic Cancer Plan for Cambridge, which embraces basic science, translational research and clinical excellence. In particular he is leading plans to develop a revolutionary Cancer Research on the Cambridge Biomedical Campus with the UK’s first National Institute for the Early Detection of Cancer.
Established in 2013, the Burkitt Medal is designed to recognise people with the integrity, compassion and dedication matching that of Denis Burkitt, a Trinity graduate, who is known for his discovery of Burkitt lymphoma. Nominees should demonstrate extraordinary achievement and advancement in the field of cancer internationally.
Denis Parsons Burkitt (28 February 1911 – 23 March 1993), surgeon, was born in Enniskillen, County Fermanagh, Ireland. He was the son of James Parsons Burkitt, a civil engineer. Aged eleven Denis lost his right eye in an accident. He attended Portora Royal School in Enniskillen and Dean Close School, England. In 1929 he applied to Trinity College Dublin to study his father’s profession, engineering, despite a tutor writing to his father expressing doubts if Burkitt would be capable of earning a degree. During his first year at Trinity he joined Room 40, a small group of undergraduates, who met regularly for prayer and Bible study, and committed his life to Jesus Christ. His religious convictions would be a driving force for the rest of his life. Soon after his commitment to Christianity, he felt that God was calling him to devote his life to medicine. He changed his study to medicine and graduated with his MB on 5 July, 1935. After graduating from Trinity College Dublin he continued his surgical training and obtained Fellowship of the Royal College of Surgeons in Edinburgh in 1938. He went on to write his MD entitled ‘Spontaneous rupture of abdominal viscera’ in 1947.
While serving as a ship’s surgeon in 1938, Burkitt decided he would be a surgeon first and a missionary second and hoped to work with the Colonial Service in West Africa. During his five-year sojourn as an army surgeon during World War Two, he married Olive Mary Rogers, a trainee nurse he had met while working as the Resident Surgical Officer at the Prince of Wales Hospital in Plymouth. Denis and Olive had three daughters Judy Howard, Cas and Rachel.
Despite having his application to the Colonial Office being turned down on account of his loss of sight, Burkitt passed a medical and enlisted into the Royal Army Medical Corps. He was posted to a military hospital in Mombasa. Burkitt 'made two major contributions to medical science related to his experience in Africa.
The first was the description, distribution, and ultimately, the etiology of a pediatric cancer that bears his name Burkitt's lymphoma'. Burkitt in 1957 observed a child with swellings in the angles of the jaw. Having an intensely enquiring mind, Burkitt took the details of these cases to the records department, which showed that jaw tumours were common, were often associated with other tumours at unusual sites in children in Uganda. He kept copious notes and 'concluded that these apparently different childhood cancers were all manifestations of a single, hitherto unrecognized tumour complex'. Burkitt published A sarcoma involving the jaws of African children. The newly identified cancer became known as 'Burkitt's lymphoma. He went on to map the geographical distribution of the tumour. Burkitt, together with Dr Dennis Wright, published a book titled 'Burkitt's Lymphoma' in April 1970.
His second major contribution came when, on his return to Britain, Burkitt compared the pattern of diseases in African hospitals with Western diseases. He concluded that many Western diseases which were rare in Africa were the result of diet and lifestyle. He wrote a book Don't Forget Fibre in your Diet, which was an international bestseller.
Although one study showed that people who eat very low levels of fiber—less than 10 grams per day—had an 18 percent higher risk of colorectal cancer, the more general idea that colon cancer is a fiber deficiency disease is now generally considered incorrect by cancer researchers. Nevertheless, research suggests that a diet high in dietary fiber is advised as a precaution against other diseases such as heart disease and diabetes. He had an alternative theory, published in numerous articles and books, that the use of the natural squatting position for defecation protects the natives of Africa and Asia from gastrointestinal diseases.
Burkitt was president of the Christian Medical Fellowship and wrote frequently on religious/medical themes. He received the Bower Award and Prize in 1992. He died on 23 March 1993 in Gloucester and was buried in Bisley, Gloucestershire, England.
Deadline for submissions – 1 March 2017
Completed forms to be returned to Professor Orla Sheils, Chair of the Selection Committee, by e-mail: CONFSM@tcd.ie
Burkitt Medal Awardee 2016 Paul Brennan, PhD
Paul Brennan is the Head of the Genetics Section of the International Agency for Research on Cancer (IARC), Lyon, France. IARC is the specialised cancer agency of the World Health Organization (WHO) with the objective to promote international collaboration in cancer research. Dr Brennan's primary area of work is conducting very large multi-partner studies that aim to use genetics to understand the causes of cancer. This is done by exploring the genome of individuals who develop cancer, in order to identify clues as to why they are more susceptible. It also involves investigating the genomes of the tumours, in order to identify what triggered the tumour in the first place. His group works with colleagues in many different parts of the world, with active studies underway in central and eastern Europe, central and south-east Asia, and Latin America. Among others, Dr Brennan has collaborators in Trinity College Dublin. Dr Brennan and his colleagues at IARC have made an outstanding contribution to promoting international collaboration in the study of cancer for the ultimate benefit of those affected by the disease.
Burkitt Medal Awardee 2015 – Riccardo Dalla-Favera, MD, MSc
Riccardo Dalla-Favera is Professor of Pathology & Cell Biology and Director, Institute for Cancer Genetics at Columbia University, New York, USA. Professor Dalla-Favera’s career started with his pioneering work on the cloning and chromosomal mapping of human proto-oncogenes, including c-MYC. This work established the basis for the seminal work on the involvement of c-MYC in chromosomal translocations in Burkitt’s lymphoma. His research has continued to yield new insights into the pathogenesis of human B cell lymphomas, and, in particular, on the identification of the genetic lesions and biological mechanisms responsible for the development of these diseases.
Burkitt Medal Awardee 2014 – John L. Ziegler, MD, MSc
John Ziegler, Founding Director, Global Health Sciences Graduate Program University of California San Francisco (UCSF), USA, received his undergraduate degree (BA, English Literature) from Amherst College, Amherst Massachusetts, and his MD from Cornell University Medical School in New York City. Following medical house staff training at Bellevue Hospital in New York, he joined the National Cancer Institute (NCI) in 1966, beginning a life-long career in cancer research and care. In 1967 he was assigned to begin a long collaboration with Makerere University in Kampala, Uganda, studying Burkitt’s lymphoma and other indigenous cancers. Together with Ugandan counterparts, he developed curative therapies for lymphoma and established a cancer institute that today has expanded to a major center of excellence in sub Saharan Africa. After five years Ziegler returned to NCI to head clinical oncology, and in 1981 moved to UCSF. The AIDS pandemic made its first appearance in San Francisco, heralded by opportunistic infections and two malignancies – Kaposi’s sarcoma and non Hodgkin’s lymphoma. Ziegler and colleagues made important contributions to this field both in California and back in Uganda. In his later career, earning an MSc in epidemiology from the London School of Hygiene and Tropical Medicine, Ziegler headed a cancer genetics clinic at UCSF, and most recently was founding director of a global health Master’s degree.
Burkitt Medal Awardee 2013 – Murray F. Brennan, MD
Born in Auckland, New Zealand, Dr. Murray Brennan received a degree in mathematics from the University of New Zealand and a medical degree from the University of Otago in 1964. In 1970 he worked at Peter Bent Brigham Hospital, Harvard Medical School, and at the Joslin Research Laboratories. After residency at the Brigham, Dr. Brennan joined the National Cancer Institute. In 1981, he joined Memorial Sloan-Kettering Cancer Center (MSKCC) as Chief of Gastric and Mixed Tumor Service. Dr. Brennan was Chairman of the Department of Surgery at MSKCC from 1985 until June of 2006. He currently holds the Benno C. Schmidt Chair in Clinical Oncology and is Director of the International Center and Vice President for International Programs at MSKCC. He has lectured throughout the world and authored and co-authored more than 1,000 scientific papers and book chapters focusing on surgical oncology, endocrinology, metabolism, and nutrition, and is the author of a book on soft tissue sarcoma. Dr Brennan received numerous honours for his contribution to oncology. Dr. Brennan’s interest, in addition to patient care and research, has been the development of young surgeons.
The registration fee includes morning coffee, lunch, afternoon tea, reception on both days of the conference.
Conference dinner in Trinity College Dining Hall is €50 (additional to the registration fee).
You can register here
To submit abstracts visit http://www.bytesizedhost.co.uk/tcdc/.
Please note that abstract submissions will close on the 1st of September.
If you are interested in sponsoring the 2016 International Cancer Conference, please contact:
Tel: 00353 1 896 2560